(Total Views: 710)
Posted On: 08/09/2024 1:32:10 AM
Post# of 155843
Dr. Burger LL Vector Cancer patent:
METHODS FOR TREATING OR
PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI - CCR5 RECEPTOR AGENTS
Applicant : CytoDyn Inc. , 2 Vancouver , WA ( US )
Inventors : Denis BURGER , Vancouver , WA ( US ) ; Scott KELLY , Vancouver , WA
Related U.S. Application Data
Provisional application No. 62 / 882,353 , filed on Aug. 2 , 2019 ,provisional application No. 63 / 047,693 , filed on Jul . 2 , 2020
ABSTRACT
The present disclosure relates to the use of competitive inhibitors of the CCR5 receptor , such as the monoclonal antibody leronlimab , or binding fragments thereof , in the treatment or prevention of cancer .
Jump down to a couple of the #'s....
[ 0018 ] Additionally , in the present disclosure , leronlimab was found to be unexpectedly effective in preventing tumor growth in mouse models lacking T cells , indicating that leronlimab also modulates immunological responses and promote anti - tumor effects through NK cells , B cells , or both . Accordingly , the ability of leronlimab to modulate activity triggered by binding the CCR5 axis on non - T cells , for example , on NK cells , B cells , or both , was determined . Also , importantly , it was found that leronlimab is surprisingly effective in preventing tumor growth in mouse models based solely on its activity relative to non - T cells ; thus , suggesting a non - T cell therapeutic approach
[ 0022 ] In some embodiments , the present disclosure provides a method of treating , inhibiting , or preventing colon cancer metastasis comprising administering to a subject in need thereof an anti - CCR5 cell receptor binding agent comprising :
( a ) a leronlimab antibody , or binding fragment thereof ; ( b ) a nucleic acid encoding a leronlimab antibody , or binding fragment thereof
c ) a VECTOR comprising a nucleic acid encoding a leronlimab antibody , or binding fragment thereof ; ( d ) a host cell comprising ( i ) a leronlimab antibody , or binding fragment thereof ,( ii ) a nucleic acid encoding a leronlimab antibody , or binding fragment thereof , or ( iii ) a VECTOR comprising a nucleic acid encoding a leronlimab antibody , or binding fragment thereof ; or ( e ) an anti - CCR5 cell receptor binding agent that does not have CCL5 agonist activity .
Jump down to EXAMPLES section:
Example 1
Effect of Leronlimab on Kinase Activation and Phosphorylation in CD4 + T Cells
Example 2
Leronlimab Prevents Cancer in an Immunocompromised Mouse Model
Example 3
Leronlimab Slows Development of XGVHD and Enhances Anti - Tumor Activity in a Humanized
Mouse Model of Colon Cancer
Example 4
Leronlimab Reduces Lung and Liver Metastatic Lesion Growth Rate in a Humanized Mouse Model of Colon Cancer
Example 5
Leronlimab Enhances Expression of Certain Immune Cells
Example 6
Leronlimab Inhibits Tumor - Associated Angiogene
Click on the PDF link:
https://patents.google.com/patent/US20220298249A1/fr
________
Cytodyn owns all work & Formulas produced:
https://contracts.justia.com/companies/cytody...ct/397946/
Until recent Dr. Sacha activities, never looked for a Vectoring aspect, let alone in this patent application.
But I'd be damed,we have a "vector" based patent for prevention AND treatment, of Colon Cancer.
METHODS FOR TREATING OR
PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI - CCR5 RECEPTOR AGENTS
Applicant : CytoDyn Inc. , 2 Vancouver , WA ( US )
Inventors : Denis BURGER , Vancouver , WA ( US ) ; Scott KELLY , Vancouver , WA
Related U.S. Application Data
Provisional application No. 62 / 882,353 , filed on Aug. 2 , 2019 ,provisional application No. 63 / 047,693 , filed on Jul . 2 , 2020
ABSTRACT
The present disclosure relates to the use of competitive inhibitors of the CCR5 receptor , such as the monoclonal antibody leronlimab , or binding fragments thereof , in the treatment or prevention of cancer .
Jump down to a couple of the #'s....
[ 0018 ] Additionally , in the present disclosure , leronlimab was found to be unexpectedly effective in preventing tumor growth in mouse models lacking T cells , indicating that leronlimab also modulates immunological responses and promote anti - tumor effects through NK cells , B cells , or both . Accordingly , the ability of leronlimab to modulate activity triggered by binding the CCR5 axis on non - T cells , for example , on NK cells , B cells , or both , was determined . Also , importantly , it was found that leronlimab is surprisingly effective in preventing tumor growth in mouse models based solely on its activity relative to non - T cells ; thus , suggesting a non - T cell therapeutic approach
[ 0022 ] In some embodiments , the present disclosure provides a method of treating , inhibiting , or preventing colon cancer metastasis comprising administering to a subject in need thereof an anti - CCR5 cell receptor binding agent comprising :
( a ) a leronlimab antibody , or binding fragment thereof ; ( b ) a nucleic acid encoding a leronlimab antibody , or binding fragment thereof
c ) a VECTOR comprising a nucleic acid encoding a leronlimab antibody , or binding fragment thereof ; ( d ) a host cell comprising ( i ) a leronlimab antibody , or binding fragment thereof ,( ii ) a nucleic acid encoding a leronlimab antibody , or binding fragment thereof , or ( iii ) a VECTOR comprising a nucleic acid encoding a leronlimab antibody , or binding fragment thereof ; or ( e ) an anti - CCR5 cell receptor binding agent that does not have CCL5 agonist activity . Jump down to EXAMPLES section:
Example 1
Effect of Leronlimab on Kinase Activation and Phosphorylation in CD4 + T Cells
Example 2
Leronlimab Prevents Cancer in an Immunocompromised Mouse Model
Example 3
Leronlimab Slows Development of XGVHD and Enhances Anti - Tumor Activity in a Humanized
Mouse Model of Colon Cancer
Example 4
Leronlimab Reduces Lung and Liver Metastatic Lesion Growth Rate in a Humanized Mouse Model of Colon Cancer
Example 5
Leronlimab Enhances Expression of Certain Immune Cells
Example 6
Leronlimab Inhibits Tumor - Associated Angiogene
Click on the PDF link:
https://patents.google.com/patent/US20220298249A1/fr
________
Cytodyn owns all work & Formulas produced:
https://contracts.justia.com/companies/cytody...ct/397946/
Until recent Dr. Sacha activities, never looked for a Vectoring aspect, let alone in this patent application.
But I'd be damed,we have a "vector" based patent for prevention AND treatment, of Colon Cancer.
(11)
(0)
